Virtual Reality Training for Social Skills in Schizophrenia - Comparison With Cognitive Training
NCT04005794
Behavior, Mental Disorders
Nashville, Tennessee, United States
View Trial DetailsNCT Number: NCT03140475
Metacognition is the ability to introspect and report one's own mental states, or in other words to know how much one knows. It allows us to form a sense of confidence about decisions one makes in daily life, so one can commit to one option if our confidence is high, or seek for more evidence before commitment if our confidence is low. Although this function is crucial to behave adequately in a complex environment, confidence judgments are not always optimal. Notably, individuals with schizophrenia are prone to overconfidence in errors and underconfidence in correct answers. In schizophrenia, confidence is less correlated with performance compared to controls.
These aspects are held to be at the origin of delusions, disorganization, poor insight into illness and into cognitive deficit and poor social functioning.
Our study aims at identifying the cognitive and neural processes involved in metacognitive deficits in schizophrenia. Participants will perform metacognitive judgments on a low-level perceptual task (visual motion discrimination). Participants will do the first-order perceptual task by clicking on the correct answer with a mouse. During the first order task completion, the investigators will record several behavioral, physiological and neural variables. Then, participants will perform the metacognitive task with a visual analog scale.
The study will address four research questions:
* Q1: is schizophrenia associated with a decrease in metacognitive efficiency? Is the metacognitive deficit due to under- or over-confidence? * Q2: is the metacognitive impairment reflected at a decisional level as measured by behavioral variables (mouse tracking and reaction times)? * Q3: which physiological markers (EEG, skin conductance, heart rate) are predictors of metacognitive efficiency in individuals with schizophrenia and healthy controls? * Q4: which clinical symptoms correlate with metacognitive deficits?
The investigators make several hypotheses related to the previous research questions:
* Q1: the investigators expect metacognitive deficits in schizophrenia, based on results from several studies using both qualitative and quantitative measures. The investigators will rule out that quantitative deficits are not confounded with impairments in type 1 performance, with a generalized cognitive deficit in schizophrenia (lower premorbid and current Intelligence Quotient (IQ), and deficits in executive functioning and particularly in planning and working memory abilities), with depression or with statistical flaws during analysis of confidence. * Q2: the investigators expect behavioral cues (mouse tracking and reaction times) to be less correlated with confidence in patients vs. controls. The investigators thus make the hypothesis that the metacognitive deficit in schizophrenia may stem from an inability to integrate pre-decisional cues while performing an explicit metacognitive judgment. * Q3: the investigators expect physiological cues (EEG with Error-Related Negativity, Lateralized Readiness Potential and alpha suppression, and arousal of the autonomic nervous system with skin conductance and heart rate ) to be less correlated with confidence in patients vs. controls. * Q4: based on previous findings, the investigators expect that several clinical dimensions of schizophrenia may correlate with metacognitive performance. The metacognitive deficit would be greater for patients with high levels of positive and disorganized symptoms, and greater for patients with low levels of clinical and cognitive insight, and low levels of social functioning.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Observational
CHU Grenoble, Grenoble, France
SAMPLING PLAN
Sample sizes for electrophysiological recordings are based on previous a study, with 20 patients vs. 20 controls, resulting in 13 vs. 13 after outlier exclusion.
DESIGN PLAN
ANALYSIS PLAN
The groups' socio-demographic (age, sex, education), cognitive (premorbid and current IQ, and executive performance with planning and working memory) and mood (depression) characteristics will be compared using the Student t test or Χ² tests when appropriate. Only variables that significantly differ between the two groups will be included as covariates in the following analyses.
The metacognitive performance will be primarily analyzed with binomial mixed-effects models between accuracy and confidence, with group (patient vs. control) and several covariates (premorbid and current IQ, depression and executive performance with planning and working memory) as between-subject factors. Regression slope will be taken as an indicator of metacognitive performance and asymptotes as a marker of confidence bias, i.e. the tendency to report high or low confidence ratings independent of task performance. Likelihood ratio tests will assess significance.
Predecisional behavioral variables (reaction times, mouse trajectory parameters) will be added to the model in a secondary analysis after main differences between patients and controls are established. Geometric features of mouse trajectories (motion entropy on the x-axis) will be quantified using the EMOT and Mousetrap packages. Correlations between motion entropy and confidence will be quantified by R², adjusted for the number of dependent variables relative to the number of data points.
8.2. Correlation between metacognitive performance and clinical characteristics in schizophrenia
The investigators will run correlation analyses between metacognitive performance (regression slope between metacognitive judgments and accuracy of the first order task) and several clinical variables. The clinical variables will be:
8.3. Electrophysiological data Preprocessing: continuous EEG will be acquired at 1200 Hz with a 64-channels Gtec HIamp system. Signal preprocessing will be performed using custom Matlab (Mathworks) scripts using functions from the EEGLAB toolbox. Following visual inspection, artifact-contaminated electrodes will be removed for each participant, and epoching will be performed at type 1 response onset. For each epoch, the signal from each electrode will be centered to zero and average-referenced. Following visual inspection and rejection of epochs containing artifactual signals, an independent component analysis will be applied to individual data sets, followed by a semi-automatic detection of artifactual components based on measures of autocorrelation, focal channel topography, and generic discontinuity. After artifacts rejection, artifact-contaminated electrodes will be interpolated using spherical splines.
Statistical analysis: voltage amplitude will be averaged within temporal windows (e.g., 20ms), and analyzed with linear mixed effects models using R together with the lme4 and lmerTest packages. This method allows analyzing single trial data, with no averaging across condition or participants, and no discretization of confidence ratings. Models will be performed on each latency and electrode for individual trials, including raw confidence rating and accuracy as fixed effects, and random intercepts for subjects. Statistical significance for electrophysiological data within regions of interest (e.g., frontocentral and left parietal scalp regions) will be assessed after correction for false discovery rate. When possible, cluster-based permutation test will be used.
Drift-diffusion modeling will allow us to determine which aspects of reaction times during the type 1 task differ between schizophrenic patients and healthy controls (e.g., drift rate and boundary separation), and assess how such differences might determine confidence judgments, thereby allowing testing the existence of metacognitive deficits at a decisional-locus.
Only trials with reaction times between 100 ms and 6 s for the type 1 task will be kept.
Participants will be excluded in case they cannot reach 71% accuracy on the type 1 task, respond in more than 6 s in a majority of trials, or in case they do not use the confidence scale properly (e.g., no variance in confidence reports).
14.2. Heart rate Heart rate will be measured with a Gtec plethysmographic pulse sensor and quantified as a function of type 2 performance. Based on previous findings in healthy participants, the investigators expect greater confidence to be associated with faster heart rate between stimulus onset and type 2 response. The investigators will attempt to replicate these findings following the same methods as Allen and colleagues and extend it to patients.
14.3. galvanic skin response (GSR) As for heart rate, GSR will be measured with a Gtec dedicated sensor and quantified as a function of type 2 performance using the Ledalab toolbox under Matlab. To our knowledge, no study has quantified the link between GSR and metacognition so that the investigators will conduct exploratory analyses.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Repeated measures within a 2 hours long experiment
Regression slope between accuracy and confidence, in a binomial mixed-effects model including appropriate covariates (variables that are significantly different between patients and controls, among the following: age, sex, education, premorbid and current IQ, executive performance with planning and working memory; and depression)
Time frame: Repeated measures within a 2 hours long experiment
Reaction times and mouse trajectory parameters (motion entropy on the x-axis)
Time frame: Repeated measures within a 2 hours long experiment
Error-Related Negativity, Lateralized Readiness Potential and alpha suppression
Time frame: Repeated measures within a 2 hours long experiment
Asymptote of the regression line between accuracy and confidence, in a binomial mixed-effects model including appropriate covariates (variables that are significantly different between patients and controls, among the following: age, sex, education, premorbid and current IQ, executive performance with planning and working memory; and depression)
Time frame: One measure per subject, assessed during a 30 min long interview
The following items of the the Positive and Negative Syndrome Scale: P1+P3+G9+P6+P5+G1+G12+G16-N5
Time frame: One measure per subject, assessed during a 30 min long interview
The following items of the the Positive and Negative Syndrome Scale: N7+G11+G10+P2+N5+G5 +G12 +G13 +G15+G9
Time frame: One measure per subject, assessed with a 10 min long autoquestionnaire
Total score on the Birchwood Insight Scale, a self-report scale with 8 items
Time frame: One measure per subject, assessed with a 20 min long autoquestionnaire
Total score on the Beck Cognitive Insight Scale, a self-report scale with 15 items
Time frame: One measure per subject, assessed during a 20 min long interview
Total score on the Personal and Social Performance Scale
Time frame: Repeated measures within a 2 hours long experiment
Measured with a Gtec plethysmographic pulse sensor
Time frame: Repeated measures within a 2 hours long experiment
Measured with a Gtec dedicated sensor
Versailles Hospital
Other
Acronym: METASENS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04005794
Behavior, Mental Disorders
Nashville, Tennessee, United States
View Trial DetailsNCT01466439
Behavior, Behavioral Symptoms
Caen, France
View Trial DetailsNCT01749124
Behavior, Behavioral Symptoms
Long Beach, California, United States
View Trial DetailsNCT06038955
Behavior, Behavioral Symptoms
Frederiksberg, Capital Region of Copenhagen, Denmark
View Trial Details